Use of antithrombotic agents in patients with transient ischemic attacks (TIAs).21
| Event . | Recommended Therapy . | Therapeutic Options . |
|---|---|---|
| Abbreviations: ASA, acetylsalicylic acid (aspirin); ER-DP, extended-release dipyridamole. | ||
| * Neither ER-DP+ASA nor ASA alone is recommended for patients who are allergic to aspirin or unable to take low-dose aspirin. | ||
| **The recommended antithrombotic agents have not been specifically tested in patients who have experienced a TIA during ASA therapy. | ||
| TIA (atherothrombotic) | ASA 50–325 mg/d | ER-DP 200 mg+ASA 25 mg BID Clopidogrel 75 mg/d Ticlopidine 250 mg BID ASA 50–1300 mg/d |
| TIA (atherothrombotic) aspirin intolerant* or if TIA occurs during ASA therapy** | ER-DP 200 mg + ASA 25 mg BID Clopidogrel 75 mg/d | Ticlopidine 250 mg BID Warfarin (INR 2–3) ASA 50–1300 mg/d |
| TIA (cardioembolic) | Warfarin target INR 2.5 (range 2–3) | ASA 50–325 mg/d (if contraindications to warfarin) |
| Event . | Recommended Therapy . | Therapeutic Options . |
|---|---|---|
| Abbreviations: ASA, acetylsalicylic acid (aspirin); ER-DP, extended-release dipyridamole. | ||
| * Neither ER-DP+ASA nor ASA alone is recommended for patients who are allergic to aspirin or unable to take low-dose aspirin. | ||
| **The recommended antithrombotic agents have not been specifically tested in patients who have experienced a TIA during ASA therapy. | ||
| TIA (atherothrombotic) | ASA 50–325 mg/d | ER-DP 200 mg+ASA 25 mg BID Clopidogrel 75 mg/d Ticlopidine 250 mg BID ASA 50–1300 mg/d |
| TIA (atherothrombotic) aspirin intolerant* or if TIA occurs during ASA therapy** | ER-DP 200 mg + ASA 25 mg BID Clopidogrel 75 mg/d | Ticlopidine 250 mg BID Warfarin (INR 2–3) ASA 50–1300 mg/d |
| TIA (cardioembolic) | Warfarin target INR 2.5 (range 2–3) | ASA 50–325 mg/d (if contraindications to warfarin) |